fashion -WSS

fashion

author：knowledge 2025-08-12 09:08:56 - browse：4872

Closeup of a human brain affected by Alzheimer's disease, on display at the Museum of Neuroanatomy at the University at Buffalo in Buffalo, N.Y. — A brain affected by Alzheimer's disease, at the Museum of Neuroanatomy at the University at Buffalo. David Duprey/AP

Investigators on Wednesday released the first detailed case report about a patient who died after receiving lecanemab, providing a new glimpse into safety concerns surrounding the closely watched experimental Alzheimer’s drug.

An unpublished version of the report was previously written about by Science in November, one of three deaths from the lecanemab trials revealed by Science and STAT. But the published version, in the New England Journal of Medicine, will allow doctors to evaluate the case as they consider whether and how to use a treatment that could be approved by the FDA as soon as this week.

This “will have greater impact on clinicians because it is peer-reviewed and published in the New England Journal,” said Lon Schneider, an Alzheimer’s expert at University of Southern California, who was not affiliated with the work.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Malaria cases in Florida and Texas: Here’s what you need to know

WSS

Cancer drug shortages should be causing more outrage

Heart attack and stroke risk calculators need revising

Colonoscopy at 40? Study finds a possible benefit

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why are elite athletes different? Take a look at their microbes

STAT's guide to the next generation of CAR

focus

fashion

focus

Duchenne breakthrough therapy leaves behind pioneering families

Wildfire smoke exposes gaps in outdoor worker protections

How one medical school became remarkably diverse

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Moonlake's readout produced a cash windfall. Risks remain

How to save PrEP access — and even expand it

Bright Health sells Medicare Advantage business to Molina

With FDA staff opposed to Sarepta therapy, top official intervened

How one medical school became remarkably diverse

Drug repurposing or repositioning? The language matters

explore

Dobbs anniversary: the lost opportunity of abortion as health care

Guidelines to prevent youth baseball injuries need more muscle

Disclosing genetic information: not as worrisome as once feared

Why are elite athletes different? Take a look at their microbes

Donald Trump's relentless attacks on special counsel Jack Smith

Novavax promises a turnaround & Lilly roils the obesity market

entertainment

knowledge

hotspot

hotspot